Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19065946 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING OF EXON 44 OF DYSTROPHIN IN A SUBJECT | February 2025 | May 2025 | Allow | 2 | 0 | 1 | Yes | No |
| 19046824 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING | February 2025 | May 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18940209 | METHOD OF USING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | November 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18939894 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | November 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18927497 | POLYPEPTIDE COMPRISING A SINGLE-DOMAIN ANTIBODY VARIABLE REGION THAT BINDS DELTA-LIKE LIGAND 3 (DLL3) AND METHOD OF USE THEREOF TO MAKE A RADIONUCLIDE COMPLEX | October 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18896799 | METHOD OF TREATING AN INTERLEUKIN-11-ASSOCIATED OR -MEDIATED FIBROTIC DISEASE OR CONDITION BY ADMINISTERING AN ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODY | September 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18759724 | COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY | June 2024 | June 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18656654 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | May 2024 | August 2024 | Allow | 4 | 1 | 1 | No | No |
| 18656672 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | May 2024 | August 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18651734 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHODS OF USE THEREOF TO TARGET DYSTROPHIN AND TO TREAT DUCHENNE MUSCULAR DYSTROPHY | May 2024 | January 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18629444 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE WHICH BINDS CLAUDIN-6 and CLAUDIN-9 | April 2024 | September 2024 | Allow | 6 | 1 | 1 | No | No |
| 18593157 | ANTI-HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP) MONOCLONAL ANTIBODY AND USE THEREOF TO TREAT DISEASE | March 2024 | June 2025 | Allow | 15 | 1 | 1 | No | No |
| 18590853 | ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODIES | February 2024 | September 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18431764 | NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTIBODIES AND OTHER PROTEINS THAT BIND FOLATE RECEPTOR ALPHA | February 2024 | January 2025 | Allow | 12 | 1 | 1 | No | No |
| 18542929 | POLYNUCLEOTIDES ENCODING ANTI-GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP1R) ANTAGONIST ANTIBODIES | December 2023 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18528957 | METHOD OF TREATING AN OCULAR CONDITION BY ADMINISTERING MULTISPECIFIC ANTIBODIES THAT ACTIVATES TIE2 AND BINDS A RECEPTOR TYROSINE KINASE AGONIST | December 2023 | April 2025 | Allow | 17 | 0 | 1 | No | No |
| 18384230 | HUMANIZED ANTIBODIES RECOGNIZING SORTILIN | October 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18383121 | LYOPHILIZED POWDER CONFIGURED FOR RECONSTITUTION AS A LIQUID PHARMACEUTICAL FORMULATION WITH REDUCED VISCOSITY AND METHOD OF PREPARING THEREOF | October 2023 | April 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18481578 | BINDING AGENTS THAT BIND OX40 (CD134) AND METHOD OF USE THEREOF TO TREAT DISEASE | October 2023 | May 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18468580 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHODS OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18467851 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | September 2023 | April 2024 | Allow | 7 | 1 | 1 | No | No |
| 18463037 | COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES TO HUMAN ADAMTS5 AND NERVE GROWTH FACTOR | September 2023 | April 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18456323 | ANTIBODIES SPECIFIC FOR HUMAN COMPLEMENT C5A RECEPTOR (C5AR) | August 2023 | April 2024 | Allow | 7 | 1 | 1 | No | No |
| 18450222 | METHODS OF TREATING A SUBJECT SUFFERING FROM RHEUMATOID ARTHRITIS WITH ANTI-TNF THERAPY BASED IN PART ON A TRAINED MACHINE LEARNING CLASSIFIER | August 2023 | April 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18365505 | METHOD OF TREATING AN EYE-RELATED DISORDER BY ADMINISTERING AN ANTI-INTERLEUKIN-4 RECEPTOR ALPHA (ANTI-IL-4RA) ANTIBODY | August 2023 | April 2024 | Allow | 8 | 2 | 1 | Yes | No |
| 18365536 | METHODS FOR TREATING DIGITALLY-IDENTIFIED IL-4/IL-13 RELATED DISORDERS | August 2023 | December 2024 | Abandon | 16 | 2 | 1 | Yes | No |
| 18347626 | NUCLEIC ACIDS ENCODING FCRN-BINDING ANTIBODIES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF TO MAKE ANTIBODIES | July 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
| 18344311 | ANTIBODIES WITH IMPROVED STABILITY TO INTESTINAL DIGESTION, POLYNUCLEOTIDES THEREOF AND METHODS OF USE THEREOF TO TREAT DISEASE | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18212542 | METHODS OF TREATING PATIENTS AFFLICTED WITH IRRITABLE BOWEL SYNDROME, INFLAMMATORY BOWEL DISEASE OR CHRONIC GASTROINTESTINAL FUNCTIONAL DISORDERS BASED ON ASSESSMENT OF INTESTINAL BARRIER FUNCTION | June 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18337901 | MODULATION OF IFI16 AND STING ACTIVITY | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18335636 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | June 2023 | June 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18329069 | METHODS OF TREATING PNEUMONIA OR RESPIRATORY FAILURE ASSOCIATED WITH COVID-19 BY ADMINISTERING AN ANTI-LIGHT ANTIBODY | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18323543 | METHOD OF INCREASING PROTEIN PRODUCTION IN A CHINESE HAMSTER OVARY PERFUSION CELL CULTURE | May 2023 | April 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18314117 | ANTIBODIES THAT BIND TO C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER D (CLEC2D) | May 2023 | July 2025 | Allow | 26 | 1 | 1 | No | No |
| 18309450 | METHOD OF REDUCING OR TREATING FIBROSIS BY ADMINISTERING AN INTERLEUKIN-2/TGF-BETA RECEPTOR FUSION POLYPEPTIDE | April 2023 | February 2025 | Allow | 21 | 1 | 1 | No | No |
| 18033600 | TYPE-II VNAR POLYPEPTIDES WHICH BIND HUMAN TFR-1, ENCODING NUCLEIC ACIDS THEREOF AND METHOD OF USE THEREOF | April 2023 | August 2024 | Allow | 16 | 1 | 1 | No | No |
| 18305235 | METHOD OF TREATING TYPE 1 INTERFERON (IFN)-MEDIATED DISEASE USING A SUBCUTANEOUS DOSING REGIMEN COMPRISING ANIFROLUMAB | April 2023 | May 2024 | Allow | 13 | 2 | 2 | No | No |
| 18304883 | METHOD OF ADMINISTERING LAPATINIB TO A CANINE TO TREAT BLADDER CANCER HARBORING A BRAF MUTATION | April 2023 | April 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18184741 | MUSCLE-TARGETING COMPLEX COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | March 2023 | July 2023 | Allow | 5 | 2 | 0 | No | No |
| 18184905 | METHODS OF PRODUCING MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | March 2023 | August 2023 | Allow | 5 | 1 | 1 | No | No |
| 18182166 | NUCLEIC ACIDS ENCODING, AND METHODS OF PRODUCING, ANTIBODIES THAT BIND HUMAN CHEMOKINE (C-C MOTIF) RECEPTOR 8 (CCR8) | March 2023 | January 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18181450 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | March 2023 | July 2024 | Abandon | 16 | 0 | 0 | No | No |
| 18168519 | METHODS OF ENRICHING OR AMPLIFYING NUCLEIC ACIDS IN A SAMPLE FROM A PATIENT WITH INFLAMMATORY BOWEL DISEASE | February 2023 | April 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18164206 | ANTIBODIES AGAINST CARCINOEMBRYONIC ANTIGENS | February 2023 | July 2023 | Allow | 6 | 1 | 1 | Yes | No |
| 18019001 | INTERFERON-GAMMA R2 (IFNGR2) BINDING MOLECULES COMPRISING SINGLE-DOMAIN ANTIBODIES AND METHOD OF USE THEREOF TO TREAT AUTOIMMUNE AND INFLAMMATORY DISEASES | January 2023 | February 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18162447 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS, ENCODING POLYNUCLEOTIDES AND USE OF RECEPTORS THEREOF TO TREAT CANCER | January 2023 | May 2024 | Allow | 15 | 2 | 1 | No | No |
| 18158852 | RECOMBINANT VIRUS VECTOR (RVV) FOR INHIBITING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVITY AND METHOD OF MAKING AN AGENT/TARGET CELL COMPLEX TO INCREASE CETUXIMAB-LIKE PROTEIN (CLP) PRODUCITON | January 2023 | April 2025 | Allow | 27 | 3 | 1 | Yes | No |
| 18017593 | IL28RA BINDING MOLECULES COMPRISING A SINGLE-DOMAIN ANTIBODY | January 2023 | July 2024 | Allow | 17 | 2 | 1 | No | No |
| 18095753 | METHOD OF TREATING DISEASES OF THE KIDNEY AND URINARY TRACT BY ADMINISTERING A PEPTIDE-LINKED THERAPEUTIC AGENT | January 2023 | November 2024 | Allow | 22 | 0 | 1 | Yes | No |
| 18091361 | METHODS FOR TREATING CANCER USING SOLUBLE FORMS OF PSGL-1 AND FUSION MOLECULES THEREOF | December 2022 | November 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 18065371 | METHODS OF TREATING CANCER BY ADMINISTERING AN ANTIBODY-DRUG CONJUGATE TARGETING HUMAN CLAUDIN 18.2 | December 2022 | February 2025 | Allow | 26 | 1 | 1 | No | No |
| 18079307 | METHOD FOR PRODUCING BISPECIFIC ANTIBODIES COMPRISING A Y436A FC-REGION MUTATION FOR IMPROVED PROTEIN A-BINDING | December 2022 | May 2025 | Allow | 29 | 1 | 1 | No | No |
| 18062265 | Compositions and Methods for Treating Cancer | December 2022 | February 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18056029 | ENGINEERED EXTRACELLULAR VESICLES COMPRISING FUSION PROTEINS | November 2022 | March 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18055340 | TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR IGM ANTIBODIES AND USES THEREOF | November 2022 | February 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18050234 | TRANSFERRIN RECEPTOR (TFR)-SELECTIVE BINDING PEPTIDES CAPABLE OF CROSSING THE BLOOD BRAIN BARRIER, ENCODING NUCLEIC ACIDS THEREOF AND METHODS OF USE THEREOF | October 2022 | January 2025 | Allow | 27 | 1 | 1 | No | No |
| 17974949 | ANTI-HLA-DQ2.5 ANTIBODY AND METHOD OF USE THEREOF TO TREAT CELIAC DISEASE | October 2022 | March 2025 | Allow | 28 | 1 | 1 | No | No |
| 18045592 | HUMAN ANTIBODIES TO THE HUMAN GLUCAGON RECEPTOR (HGCGR) AND METHODS OF USE THEREOF TO LOWER BLOOD GLUCOSE OR KETONE LEVELS | October 2022 | November 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17936483 | METHODS OF USING MUSCLE TARGETING COMPLEXES TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY OR A DISEASE ASSOCIATED WITH MUSCLE WEAKNESS | September 2022 | February 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 17934441 | METHOD OF ASSESSING THE EFFICACY OF A TEST AGENT FOR MODULATING PROGRAMMED DEATH 1 (PD-1) SIGNALING BY USING ANTI-PHOSPHOTYROSINYLATED PD-1 MONOCLONAL ANTIBODIES | September 2022 | January 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 17930545 | METHOD OF DEPLETING TARGET ANTIGEN-SPECIFIC ANTIBODY FROM A PATIENT BY ADMINISTERING A FUSION PROTEIN (SELDEG) FOR SELECTIVELY DEPLETING ANTIGEN-SPECIFIC ANTIBODIES | September 2022 | April 2025 | Allow | 32 | 2 | 1 | No | No |
| 17823854 | OLIGOMERIC COMPOUNDS FOR REDUCING DMPK EXPRESSION | August 2022 | July 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17822757 | ARRAY-BASED PEPTIDE LIBRARIES FOR THERAPEUTIC ANTIBODY CHARACTERIZATION | August 2022 | June 2024 | Abandon | 22 | 2 | 2 | Yes | No |
| 17821199 | STABLE ANTIBODY VARIABLE DOMAIN FRAMEWORK COMBINATIONS | August 2022 | November 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17874239 | POLYNUCLEOTIDES ENCODING ANTIBODIES WHICH BIND THE EC3 DOMAIN OF CADHERIN-6 (CDH6) AND POSSESS INTERNALIZATION ABILITY | July 2022 | October 2024 | Allow | 27 | 1 | 1 | No | No |
| 17815110 | CHIMERIC TRANSMEMBRANE PROTEIN COMPRISING ANTIBODY DIMERIZATION DOMAINS AND A TYPE I CYTOKINE RECEPTOR ENDODOMAIN, ENCODING NUCLEIC ACIDS THEREOF AND METHODS OF USE THEREOF | July 2022 | October 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17864000 | METHODS FOR REDUCING EOSINOPHILIC INFILTRATION BY ADMINISTERING AN ANTI-INTERLEUKIN-4 RECEPTOR (IL4R) ANTIBODY | July 2022 | December 2024 | Allow | 30 | 1 | 1 | No | No |
| 17855510 | NUCLEIC ACIDS ENCODING AND METHODS OF PRODUCING PROTEINS COMPRISING ANTIBODY CHAINS | June 2022 | September 2024 | Allow | 26 | 1 | 1 | No | No |
| 17846738 | METHODS OF DELIVERING AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | June 2022 | September 2022 | Allow | 3 | 1 | 0 | Yes | No |
| 17842293 | METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE BASED ON A CYTOKINE/CHEMOKINE PANEL | June 2022 | November 2024 | Allow | 29 | 1 | 1 | Yes | No |
| 17804396 | A METHOD OF TREATING AN OCULAR CONDITION BY ADMINISTERING A HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-Beta) | May 2022 | July 2024 | Allow | 26 | 2 | 1 | No | No |
| 17752710 | A VHH IMMUNOGLOBULIN CHAIN VARIABLE DOMAIN THAT BINDS TO IL-7R AND METHODS OF USE THEREOF FOR TREATING AUTOIMMUNE AND/OR INFLAMMATORY DISEASES | May 2022 | February 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17740849 | METHOD OF PROMOTING A T-CELL RESPONSE OR TREATING CANCER BY ADMINISTERING AN ANTAGONIST TO HUMAN C-TYPE LECTIN-LIKE RECEPTOR-1 (CLEC-1) | May 2022 | May 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17661450 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | April 2022 | January 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 17772350 | ANTI-INTERLEUKIN-4 RECEPTOR (IL-4R) SINGLE-DOMAIN ANTIBODY, ENCODING POLYNUCLEOTIDE AND METHODS OF MAKING AND USING THE ANTIBODY FOR IL-4R DETECTION AND DISEASE TREATMENT | April 2022 | February 2024 | Allow | 22 | 1 | 1 | No | No |
| 17720956 | METHODS FOR DIAGNOSING AN INFLAMMATORY BOWEL DISEASE BASED ON SOLUBLE TUMOR NECROSIS FACTOR II (sTNFRII) LEVELS IN A PATIENT SAMPLE AND TREATING THEREAFTER | April 2022 | February 2025 | Allow | 34 | 2 | 1 | No | No |
| 17714032 | METHODS OF TREATING A TUMOR BY ADMINISTERING A CLAUDIN-6 (CLDN6) OR CLDN9 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | April 2022 | April 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17709712 | METHODS OF TREATING CANCER | March 2022 | April 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17706839 | Single Domain Antibodies to Programmed Cell Death (PD-1) | March 2022 | February 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17698823 | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN CHAIN VARIABLE DOMAINS WHICH BIND TO INTERLEUKIN-6 RECEPTOR (IL-6R) AND METHODS OF USE THEREOF TO TREAT AUTOIMMUNE AND INFLAMMATORY DISEASES | March 2022 | April 2024 | Allow | 25 | 1 | 1 | No | No |
| 17695081 | PSGL-1 Antagonists and Uses Thereof | March 2022 | February 2024 | Abandon | 23 | 0 | 1 | No | No |
| 17673691 | A METHOD OF TREATING OR AMELIORATING A PATHOGENIC INFECTION BY ADMINISTERING AN INTERLEUKIN-2/TGF-BETA RECEPTOR FUSION POLYPEPTIDE | February 2022 | January 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17671707 | METHODS OF INTRAVENOUISLY DELIVERING ANTI-TRANSFERRIN ANTIBODY/OLIGONUCLEOTIDE COMPLEXES TO SUBJECTS HAVING MUSCULAR DYSTROPHY | February 2022 | June 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17670398 | METHODS OF TREATING HLA-E-EXPRESSING CANCERS BY ADMINISTERING ANTIBODIES WHICH BIND HUMAN NATURAL KILLER CELL INHIBITORY RECEPTOR GROUP 2A (NKG2A) | February 2022 | May 2024 | Allow | 27 | 2 | 1 | No | No |
| 17668825 | METHOD OF TREATING SKIN TISSUE DAMAGE BY TOPICALLY ADMINISTERING A BI-SPECIFIC PROTEIN COMPRISING A HUMAN INSULIN-LIKE GROWTH FACTOR VARIANT AND A HUMAN ANNEXIN A5 VARIANT | February 2022 | June 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17668807 | NUCLEIC ACID MOLECULES ENCODING ANTIBODIES WHICH BIND NATURAL KILLER CELL INHIBITORY RECEPTOR GROUP 2A PROTEIN (NKG2A) | February 2022 | January 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17632327 | METHOD OF TREATING TRANSITIONAL CELL CARCINOMA IN A CANINE BY ADMINISTERING LAPATINIB, WHEREIN THE CARCINOMA HARBORS A BRAF MUTATION | February 2022 | August 2024 | Allow | 31 | 1 | 1 | No | No |
| 17580970 | ANTIGEN BINDING MOLECULES COMPRISING A TNF FAMILY LIGAND TRIMER | January 2022 | August 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17580980 | METHODS OF TREATING CANCER BY ADMINISTERING TUMOR NECROSIS FACTOR (TNF) FAMILY LIGAND TRIMER-CONTAINING ANTIGEN-BINDING MOLECULES | January 2022 | May 2024 | Allow | 28 | 1 | 1 | No | No |
| 17563149 | BISPECIFIC ANTIBODIES WHICH BIND BLOOD COAGULATION FACTOR VIII AND HAVE ENHANCED ACTIVITY, AND METHODS OF USE THEREOF FOR TREATING BLEEDING AND ASSOCIATED CONDITIONS | December 2021 | August 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17559022 | METHODS OF TREATING AN INFLAMMATORY DISORDER BY ADMINISTERING AN ANTIBODY WHICH BINDS TO A CONNEXIN CX43 HEMICHANNEL | December 2021 | July 2024 | Allow | 31 | 1 | 1 | No | No |
| 17556714 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | December 2021 | September 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17620030 | POLYNUCLEOTIDES ENCODING, AND METHOD OF MAKING, A POLYPEPTIDE COMPRISING A VHH WHICH BINDS INTERLEUKIN- RECEPTOR (IL-7R) | December 2021 | October 2024 | Allow | 34 | 0 | 1 | Yes | No |
| 17550787 | METHOD OF TREATING AGING-ASSOCIATED COGNITIVE IMPAIRMENT BY REDUCING CCR3 | December 2021 | October 2023 | Allow | 22 | 1 | 1 | No | No |
| 17543697 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND METHOD OF USE THEREOF FOR TREATING A TUMOR | December 2021 | August 2022 | Allow | 8 | 1 | 1 | No | No |
| 17542698 | METHODS FOR INDUCIBLE EXPRESSION | December 2021 | January 2025 | Abandon | 37 | 3 | 1 | No | No |
| 17535100 | METHOD FOR TREATING MYELOFIBROSIS BY ADMINISTERING A TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR ANTAGONIST | November 2021 | February 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17532193 | METHOD OF USING AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATABLE ANTIBODY TO DETECT THE PRESENCE OR ABSENCE OF A CLEAVING AGENT AND EGFR | November 2021 | July 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17530209 | ANTIBODY-DRUG CONJUGATES TARGETING HUMAN CLAUDIN 18.2 | November 2021 | September 2022 | Allow | 10 | 1 | 1 | No | No |
| 17529794 | PHARMACEUTICAL FORMULATIONS COMRPISING ANTI-RANKL ANTIBODIES AND AN AROMATIC AMINO ACID COMPRISING A PHENYL OR AN INDOLE | November 2021 | October 2023 | Allow | 23 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LANDSMAN, ROBERT S.
With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 30.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LANDSMAN, ROBERT S works in Art Unit 1647 and has examined 1,550 patent applications in our dataset. With an allowance rate of 70.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 25 months.
Examiner LANDSMAN, ROBERT S's allowance rate of 70.2% places them in the 25% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LANDSMAN, ROBERT S receive 1.48 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LANDSMAN, ROBERT S is 25 months. This places the examiner in the 65% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +24.4% benefit to allowance rate for applications examined by LANDSMAN, ROBERT S. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 37.4% of applications are subsequently allowed. This success rate is in the 82% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 77.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 80.4% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 81.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.2% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.0% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.4% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.